Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | IDE | P14735 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 6/20 | 0.49 |
| ▸ | CA1 | P00915 | 6/20 | 0.49 |
| ▸ | CA2 | P00918 | 6/20 | 0.49 |
| ▸ | CA9 | Q16790 | 6/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.47 |
| ▸ | HLCS | P50747 | 1/20 | 0.46 |
| ▸ | PTPRF | P10586 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Homocysteine SCHEMBL565713 | 1.00 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL10140261 | 0.94 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL2458624 | 0.94 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL4624128 | 0.87 | TDP1 (0.65) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL29512013 | 0.85 | TDP1 (0.63) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31378060 | 0.85 | TDP1 (0.63) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL739034 | 0.85 | TDP1 (0.63) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31248180 | 0.85 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31378057 | 0.85 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL5817718 | 0.84 | HLCS (0.63) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2020-08-20 | — | — | US | disclosed |
| US-10463616-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190054021-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. | 2019-02-21 | — | — | US | disclosed |
| US-10004686-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-9943602-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9145453-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-8846053-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140243430-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130267462-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120035105-A1 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments | SDG, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | TDP1 4742/4885MEN1 1477/4885ABL1 3308/4885 |
| US-10004686-B2 | Lipid construct for delivery of insulin to a mammal | INSR, IAPP, GPR119 | TDP1 4882/4885MEN1 1400/4885ABL1 3769/4885 |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | TDP1 4742/4885MEN1 1477/4885ABL1 3308/4885 |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | TDP1 4650/4885MEN1 1077/4885ABL1 3190/4885 |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4819/4885MEN1 966/4885ABL1 4375/4885 |
| US-20190054021-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | TDP1 4882/4885MEN1 1400/4885ABL1 3769/4885 |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | TDP1 4819/4885MEN1 966/4885ABL1 4375/4885 |
| US-20120035105-A1 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments | IAPP, IDE, INSR | TDP1 2829/4885MEN1 1048/4885ABL1 2517/4885 |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | TDP1 4882/4885MEN1 1400/4885ABL1 3769/4885 |
| US-10463616-B2 | Lipid construct for delivery of insulin to a mammal | INSR, IAPP, GPR119 | TDP1 4882/4885MEN1 1400/4885ABL1 3769/4885 |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | TDP1 4882/4885MEN1 1400/4885ABL1 3769/4885 |
| US-20140243430-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, LIPC, FABP6 | TDP1 4650/4885MEN1 1077/4885ABL1 3190/4885 |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4819/4885MEN1 966/4885ABL1 4375/4885 |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | TDP1 4650/4885MEN1 1077/4885ABL1 3190/4885 |
| US-20130267462-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | TDP1 4882/4885MEN1 1400/4885ABL1 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.